EBMT-EHA CAR-T 2019 | CAR T-cell therapy and transplantation for hematological malignancies

Arnon Nagler

Arnon Nagler, MD, from Chaim Sheba Medical Center, Tel-Aviv, Israel, speaks at the 1st European CAR T-Cell Meeting, held in Paris, France, co-organized by the European Society for Blood & Marrow Transplantation (EBMT) and the European Hematology Association (EHA). Prof. Nagler reports that despite the promising results of CAR T-cell therapy, the therapy is still in a premature stage for replacing transplant treatments and stresses the need to resolve the limitations of CAR T-cell therapy before it can become a routine intervention.

Share this video